| pubmed-article:15187780 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0016169 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C2931133 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0027778 | lld:lifeskim |
| pubmed-article:15187780 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:15187780 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15187780 | pubmed:dateCreated | 2004-6-9 | lld:pubmed |
| pubmed-article:15187780 | pubmed:abstractText | The purpose of this study was to describe the clinical experience with the anti-tumor necrosis factor chimeric monoclonal antibody, infliximab, in pediatric patients with Crohn disease in The Netherlands. | lld:pubmed |
| pubmed-article:15187780 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15187780 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15187780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15187780 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15187780 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15187780 | pubmed:issn | 0277-2116 | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:RingsEdmond... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:EscherJohanna... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:HouwenRoderic... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:DerkxBert H... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:TaminiauJan... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:BouquetJanJ | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:SchweizerJoac... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:TolboomJules... | lld:pubmed |
| pubmed-article:15187780 | pubmed:author | pubmed-author:NorbruisObbe... | lld:pubmed |
| pubmed-article:15187780 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15187780 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:15187780 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15187780 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15187780 | pubmed:pagination | 46-52 | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:meshHeading | pubmed-meshheading:15187780... | lld:pubmed |
| pubmed-article:15187780 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15187780 | pubmed:articleTitle | Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. | lld:pubmed |
| pubmed-article:15187780 | pubmed:affiliation | Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands. l.deridder@amc.uva.nl | lld:pubmed |
| pubmed-article:15187780 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15187780 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15187780 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15187780 | lld:pubmed |
